Go to Page # Page of 53
loading

The Epicutaneous Immunotherapy Company

 DBV Technologies
  8th-May-2018
Description: This presentation contains forward looking statements including, but not limited to, statements concerning the outcome or success of DBVs clinical trials; its ability to successfully gain regulatory approvals and commercialize products; its ability to successfully advance its pipeline of product candidates; the rate and degree of market acceptance of its products; and its ability to develop sales and marketing capabilities.
Views: 2879
Domain: Medical
Category: Therapy
Contributing Organization: DBV Technologies
 ‐ More of their Presentations
Contents:
The Epicutaneous
Immunotherapy
Company
©Genoskin

April 2018

Safe Harbor
This presentation contains forward looking statements including, but not limited to, statements concerning the outcome or
success of DBV’s clinical trials; its ability to successfully gain regulatory approvals and commercialize products; its ability to
successfully advance its pipeline of product candidates; the ... See more

The Epicutaneous Immunotherapy Company

This presentation contains forward looking statements including, but not limited to, statements concerning the outcome or success of DBVs clinical trials; its ability to successfu

DBV Technologies
07 March, 2018